Drug
Brexanolone clinical trials
Also written SAGE-547 and LPCN 1154A.
- studies test it
- 27
- open now
- 3
- in phase 3
- 7
- first study started
- 2013
Keep track of what changes. Save the brexanolone studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
26 studies that test it; most in 2015 (4); 1 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 4 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 6
- Phase 2
- 10
- Phase 3
- 7
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 13
Supernus Pharmaceuticals, Inc. (9) · Sage Therapeutics (3) · University of Arizona (2) · Yale University (2) · Lipocine Inc. (2) · Roberta Brinton (1) · University of North Carolina, Chapel Hill (1) · University of Southern California (1)
Studies
Open first, then newest update. How each study uses brexanolone is read from its arms, and is right about nine times in ten.
Testing it · 27
- Allopregnanolone in Chronic Complex Traumatic Brain InjuryNot yet recruitingPhase 2VA Office of Research and DevelopmentNCT04003285Written as Allopregnanolone
- Pregnenolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding StudyNot yet recruitingPhase 2Pharmacotherapies for Alcohol and Substance Use Disorders AllianceNCT06580444Written as Brexanolone
- Brexanolone Lifting Outcomes Of MomsRecruitingPhase 3Lipocine Inc.NCT07822321Written as LPCN 1154A
- Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's DiseaseActive, not recruitingPhase 2University of ArizonaNCT04838301Written as Allopregnanolone
- An Open Label Pilot Study of IV Brexanolone for the Treatment of Post-Traumatic Stress DisorderTerminatedPhase 4Donald Jeffrey NewportNCT05254405Written as Brexanolone Injection [Zulresso]
- Allopregnanolone as a Regenerative Treatment for Parkinson's DiseaseCompletedPhase 1Roberta BrintonNCT06263010Written as Allopregnanolone
- Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular StudyTerminatedPhase 1University of ArizonaNCT03748303Written as Allopregnanolone
- A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPDCompletedPhase 3Lipocine Inc.NCT06979544Written as LPCN 1154A
- Study on Allopregnanolone and Depression in Perimenopausal WomenTerminatedPhase 4Brigham and Women's HospitalNCT05329779Written as brexanolone
- Utility of Brexanolone to Target Stress-induced Alcohol Use Among Men and Women With Posttraumatic Stress DisorderActive, not recruitingPhase 1Yale UniversityNCT05223829Written as Brexanolone
- A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)CompletedPhase 3Supernus Pharmaceuticals, Inc.NCT02942004Written as SAGE-547 60 μg/kg/h
- A Study With SAGE-547 for Super-Refractory Status EpilepticusCompletedPhase 3Supernus Pharmaceuticals, Inc.NCT02477618Written as SAGE-547
- Evaluate SAGE-547 in Female Participants With Severe Postpartum DepressionCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT02285504Written as SAGE-547
- Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status EpilepticusCompletedPhase 1/2Supernus Pharmaceuticals, Inc.NCT02052739Written as SAGE-547
- A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)CompletedPhase 3Supernus Pharmaceuticals, Inc.NCT03665038Written as Brexanolone
- A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)CompletedPhase 3Supernus Pharmaceuticals, Inc.NCT02942017Written as SAGE-547 90 μg/kg/h
- A Study To Assess The Safe-Use Conditions For Administration of ZULRESSO® in a Home SettingCompletedPhase 4Supernus Pharmaceuticals, Inc.NCT05059600Written as ZULRESSO®
- An Open-Label Study Evaluating Brexanolone in Adults With TinnitusCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT05645432Written as Brexanolone
- A Study to Evaluate SAGE-547 in Participants With Severe Postpartum DepressionCompletedPhase 2Supernus Pharmaceuticals, Inc.NCT02614547Written as SAGE-547
- Effect of Allopregnanolone on Stress-induced CravingCompletedPhase 1Yale UniversityNCT04015869Written as Allopregnanolone
Codes
What other systems call brexanolone · ClinicalTrials.gg INT000860
- MeSH (NLM) C000625635brexanoloneOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625635 | brexanolone | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.